Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
The LancetPublished 1 October 2001Open access
Jacques Fellay, Bruno Ledergerber, Enos Bernasconi, Hansjakob Furrer, Manuel Battegay, Bernard Hirschel
Citations329
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A high prevalence of toxic effects attributed to antiretroviral treatment for HIV-1 is recorded, which provides a reference for regimen-specific and compound-specific adverse events and could be useful in postmarketing analyses of toxic effects.
Abstract
We recorded a high prevalence of toxic effects attributed to antiretroviral treatment for HIV-1. Such data provides a reference for regimen-specific and compound-specific adverse events and could be useful in postmarketing analyses of toxic effects.
Keywords
Immunology and MicrobiologyMedicine
AIDSA syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2,397 Citations1998Andrew Carr, Katherine Samaras +5 more
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance is a common complication of HIV protease inhibitors and diabetes mellitus is relatively uncommon.
New England Journal of MedicineHIV-Protease Inhibitors
861 Citations1998Charles Flexner
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.
AIDSA syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
639 Citations2000Andrew Carr, J. Philip Miller +2 more
AIDSA syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
594 Citations1999T Saint-Marc, M Partisani +6 more
Body composition, body fat distribution and insulin secretion in patients taking nucleoside reverse transcriptase inhibitor (NRTI) therapy in HIV-infected patients and five out of 12 patients had a major or mild improvement in their lipodystrophy after stavudine was discontinued.
The LancetRisk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study
456 Citations2001Estebán Martínez, Amanda Mocroft +9 more
The factors associated with an increased risk for lipodystrophy with subcutaneous lipoatrophy or lipody Strophy with central obesity in patients infected with HIV-1 who were receiving HAART containing protease inhibitors are multifactorial and overlapping, and cannot be exclusively ascribed to the duration of exposure to an particular antiretroviral agent.
New England Journal of Medicine2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related Complex
390 Citations1990John S. Lambert, Mindell Seidlin +9 more
It is concluded that ddI is a promising therapeutic agent in patients with AIDS or AIDS-related complex and its efficacy is currently being evaluated in large-scale, controlled clinical trials.
Clinical Infectious DiseasesHyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study
215 Citations2001Karim Boubaker, Markus Flepp +13 more
The association between hyperlactatemia and stavudine with or without didanosine was not biased by these medications being more recently available and, therefore, being given preferentially to patients who had prolonged use of nucleoside analog reverse-transcriptase inhibitors.
Clinical Infectious DiseasesManagement of the Adverse Effects of Antiretroviral Therapy and Medication Adherence
205 Citations2000B. Max, Renslow Sherer
The common adverse drug reactions encountered with HAART, including new agents and their impact on patient adherence, are reviewed and current strategies to anticipate and mitigate adverse effects are summarized.
Annals of Internal MedicineZidovudine: Five Years Later
156 Citations1992Gavin X. McLeod, Scott M. Hammer
Zidovudine, a nucleoside analog, was the first agent proved to be effective in the management of human immunodeficiency virus type 1 (HIV-1) infection and remains the cornerstone of antiretroviral therapy.
Annals of Internal MedicineThe Case for More Cautious, Patient-Focused Antiretroviral Therapy
70 Citations2000Keith Henry
This study concludes that effective therapy has been firmly established as the standard of care in wealthy countries and rapid onset of disease and death is no longer the routine, it is important to reexamine treatment goals.
DrugsStavudine
60 Citations1999Miriam Hurst, Stuart Noble
Stavudine-containing triple therapies are effective in the treatment of antiretroviral-naive adults with HIV infection as assessed by surrogate end-points; earlier trials involving 1 or 2-drug therapy showed that stavudine can significantly improve clinical end-points.
PubMedClinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000.
45 Citations2000Philippe Sudre, Martin Rickenbach +4 more
The SHCS has had, and continues to have, a significant impact on medical practice, public health and research in Switzerland and beyond and may be model for focused and prioritised multicentre and transdisciplinary research programmes.
Clinical Infectious DiseasesThe Didanosine Expanded Access Program: Safety Analysis
39 Citations1993Isadore M. Pike, Claude Nicaise
The results of this program suggest that patients pretreated with zidovudine for prolonged periods are able to tolerate didanosine well, and hematologic parameters remained stable, especially for patients who entered the program with normal baseline values.
JAIDS Journal of Acquired Immune Deficiency SyndromesReasons for Discontinuation of First Highly Active Antiretroviral Therapy in a Cohort of Proteinase Inhibitor???Naive HIV-Infected Patients
35 Citations2001Alexander H nsel, Heiner C. Bucher +2 more
International Journal of STD & AIDSLate Onset Hepatitis and Prolonged Deterioration in Hepatic Function Associated with Nevirapine Therapy
31 Citations2000S Clarke, Patricia Harrington +4 more
The case of a 49-year-old man who developed NVP-induced prolonged hepatotoxicity 5 months after commencing antiretroviral therapy is reported.
JAIDS Journal of Acquired Immune Deficiency SyndromesReasons for Discontinuation of First Highly Active Antiretroviral Therapy in a Cohort of Proteinase Inhibitor–Naive HIV-Infected Patients
28 Citations2001Alexander Hänsel, Heiner C. Bucher +2 more
BMJAntibiotic induced fatigue.
2 Citations1993Jean‐François Bergmann, O Chassany +6 more
Exposure to the radionuclides associated with prostatic cancer was uncommon: only 3% of the controls in this study had known contamination and 11% had worked in places where contamination might have occurred.